Bruno currently serves as Senior Vice President, Clinical Development Operations at Spruce Biosciences, where he oversees clinical development operations and the execution of the company’s pipeline programs. He brings more than 30 years of experience leading clinical operations for global drug development programs, with extensive expertise in rare diseases.

Prior to joining Spruce, Bruno served as Senior Vice President, Global Clinical Operations at Opthea, where he oversaw clinical execution of a pivotal Phase 3 program in wet age-related macular degeneration and also assumed interim responsibility for medical affairs and pharmacovigilance. Previously, he led development operations at Eidos Therapeutics, a BridgeBio company, overseeing the strategic planning and execution of clinical trials for its TTR amyloidosis program and contributing to the advancement of acoramidis (ATTRUBY®) toward regulatory approval. Earlier, as Vice President of Clinical Operations at BioMarin Pharmaceutical, he directed rare disease clinical programs and global trial execution across multiple stages of development.

Earlier in his career, Bruno held positions of increasing responsibility at Roche Diagnostics, Chiron, and Hoechst Marion Roussel, now part of Sanofi. Throughout his career, the functions under his leadership have included Global Clinical Trial Management, Patient Advocacy, Medical Writing, Outsourcing and Contracts, Supply Chain Management, Clinical Data Management, Clinical Systems, Document Management, and Clinical Training.

Bruno holds a bachelor’s degree in Pharmacy from Laval University and a master’s degree in Pharmaceutical Sciences from the University of Montreal, both in Quebec, Canada.